Form 4: Director Sells TOI Shares for Tax Liabilities

The Oncology Institute Director Brad Hively sold 13,333 shares of common stock on December 15, 2025, to cover tax liabilities from a recent RSU award vesting.

Summary

• Brad Hively, a Director of The Oncology Institute, Inc. (TOI), reported a transaction involving the company's common stock.
• On December 15, 2025, Hively disposed of 13,333 shares of TOI common stock.
• The shares were sold at a volume-weighted average price of $3.7719 per share, with actual prices ranging from $3.770 to $3.785.
• The primary reason for the sale was to cover tax liabilities that arose from the vesting of a Restricted Stock Unit (RSU) award on November 20, 2025.
• Following this transaction, Hively directly beneficially owns 683,721 shares of TOI common stock.

Sentiment

Score: 5

Explanation: Neutral. The transaction is a routine sale to cover tax liabilities from RSU vesting, which is a common practice and does not inherently signal positive or negative sentiment about the company's future.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• The reporting person used the proceeds of this sale to cover tax liabilities arising from the vesting of an RSU award on November 20, 2025.

Industry Context

This transaction represents a routine insider stock sale, typically undertaken by executives to manage tax obligations associated with equity compensation, and does not inherently reflect broader industry trends or competitive positioning.

Comparison to Industry Standards

• The sale of shares by a director to cover tax liabilities upon the vesting of Restricted Stock Units (RSUs) is a standard and common practice in executive compensation across various industries. This type of transaction is not indicative of a change in company performance or a lack of confidence, but rather a mechanism to manage personal tax obligations.

Stakeholder Impact

• Shareholders: The sale represents a minor reduction in the director's direct ownership, which is a routine event and not expected to have a significant impact on shareholder value or perception.

Key Dates

Recommendation

This Form 4 reports a routine insider sale by a director to cover tax obligations arising from RSU vesting. Such transactions are common and typically do not reflect a change in the insider's confidence in the company's long-term prospects. Therefore, it provides no new fundamental information to warrant a change from a 'hold' position.

Keywords

The Oncology Institute, TOI, Brad Hively, Form 4, Insider Trading, Stock Sale, Director, RSU, Tax Liabilities, Common Stock